Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.
Xiaolun WangShelley AllenJames F BlakeVickie BowcutDavid M BriereAndrew CalinisanJoshua R DahlkeJay B FellJohn P FischerRobin J GunnJill HallinJade LaguerJ David LawsonJames MedwidBrad NewhousePhong NguyenJacob M O'LearyPeter OlsonSpencer PajkLisa RahbaekMareli RodriguezChristopher R SmithTony P TangNicole C ThomasDarin VanderpoolGuy P VigersJames G ChristensenMatthew A MarxPublished in: Journal of medicinal chemistry (2021)
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRASG12C, selective inhibition of KRASG12D presents a significant challenge due to the requirement of inhibitors to bind KRASG12D with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRASG12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRASG12D mutant xenograft mouse tumor model.